SCHEMBL2986451

SCHEMBL2986451

CN(C(=O)CNC(=O)OC(C)(C)C)c1cccc(Cl)c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.44
PYGL P06737 2/20 0.44
NPC1 O15118 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
CTSL P07711 1/20 0.43
HTR3E A5X5Y0 1/20 0.43
HTR3B O95264 1/20 0.43
HTR3A P46098 1/20 0.43
HTR3D Q70Z44 1/20 0.43
HTR3C Q8WXA8 1/20 0.43
KLKB1 P03952 1/20 0.42
KDM4E B2RXH2 1/20 0.41
FNTA P49354 1/20 0.41
FNTB P49356 1/20 0.41
IDO1 P14902 2/20 0.40
CTPS1 P17812 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29472228 0.87 IDO1 (0.38) ALDH1A1PYGLGAAMAPTNPSR1
SCHEMBL5447593 0.84 PPIB (0.50) ALDH1A1PYGLGAANPSR1CTSL
SCHEMBL17336383 0.84 MTNR1A (0.48) HSD17B1HSD17B2
SCHEMBL17336558 0.84 ALDH1A1 (0.41) ALDH1A1GAAKDM4EIDO1KMT2A
SCHEMBL8033648 0.83 ALDH1A1 (0.41) ALDH1A1PYGLNPSR1KLKB1KDM4E
SCHEMBL22289644 0.83 PARP14 (0.39)
SCHEMBL8426236 0.82 KDM4E (0.41) ALDH1A1NPC1GAAMAPTNPSR1
SCHEMBL22289671 0.82 KMT2A (0.42) CTSLKMT2A
SCHEMBL26599038 0.80 SUV39H2 (0.49) ALDH1A1NPC1GAAMAPTNPSR1
SCHEMBL29004748 0.78 HTR3E (0.51) ALDH1A1NPC1GAAMAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790726-B2 Monocyclic and bicyclic compounds and methods of use CHEMOCENTRYX, INC. (US) 2010-09-07 US disclosed
US-7786157-B2 OXO-imidazolidines as modulators of chemokine receptors CHEMOCENTRYX, INC. (US) 2010-08-31 US disclosed
EP-1931348-A4 MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE CHEMOCENTRYX INC (US) 2009-08-12 EP disclosed
US-20080269280-A1 OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS CHEMOCENTRYX, INC. (US) 2008-10-30 US disclosed
EP-1931348-A2 MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE ChemoCentryx Inc (US) 2008-06-18 EP disclosed
US-20070066583-A1 Monocyclic and bicyclic compounds and methods of use CHEMOCENTRYX, INC. (US) 2007-03-22 US disclosed
WO-2007022257-A2 MONOCYCLIC AND BICYCLIC COMPOUNDS AND METHODS OF USE CHEMOCENTRYX, INC. (US) 2007-02-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066583-A1 Monocyclic and bicyclic compounds and methods of use CCR1, CCR3, CCR4 ALDH1A1 1533/4885PYGL 3259/4885NPC1 328/4885
US-20080269280-A1 OXO-IMIDAZOLIDINES AS MODULATORS OF CHEMOKINE RECEPTORS CCR1, CCR3, CCR4 ALDH1A1 2544/4885PYGL 3815/4885NPC1 842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.